BRAVECTO QUANTUM DIN 02561352
Status: Marketed
Holder: INTERVET CANADA CORP
Health Canada record
| Active ingredient(s) | FLURALANER 2.51 G |
|---|
| Dosage form | Powder For Suspension |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 07-Nov-2025 |
|---|
| Current status date | 07-Nov-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Intervet Canada Corp. — licence 100147, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FLURALANER
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02425068 | BRAVECTO | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 112.5 MG | Marketed |
| 02425076 | BRAVECTO | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 250 MG | Marketed |
| 02425084 | BRAVECTO | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 500 MG | Marketed |
| 02425092 | BRAVECTO | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 1000 MG | Marketed |
| 02425106 | BRAVECTO | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 1400 MG | Marketed |
| 02454912 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 112.5 MG | Marketed |
| 02454920 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 250 MG | Marketed |
| 02454939 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 500 MG | Marketed |
| 02454947 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 112.5 MG | Marketed |
| 02454955 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 250 MG | Marketed |
| 02454963 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 500 MG | Marketed |
| 02454971 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 1000 MG | Marketed |
| 02454998 | BRAVECTO | INTERVET CANADA CORP | Solution | FLURALANER 1400 MG | Marketed |
| 02502259 | BRAVECTO ONE | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 560 MG | Approved |
| 02502224 | BRAVECTO ONE | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 100 MG | Marketed |
| 02502232 | BRAVECTO ONE | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 200 MG | Marketed |
| 02502240 | BRAVECTO ONE | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 400 MG | Marketed |
| 02502216 | BRAVECTO ONE | INTERVET CANADA CORP | Tablet (Chewable) | FLURALANER 45 MG | Marketed |
| 02491737 | VITRECTO | INTERVET CANADA CORP | Solution | FLURALANER 250 MG; MOXIDECTIN 12.5 MG | Marketed |
| 02491745 | VITRECTO | INTERVET CANADA CORP | Solution | FLURALANER 500 MG; MOXIDECTIN 25 MG | Marketed |
| 02491729 | VITRECTO | INTERVET CANADA CORP | Solution | FLURALANER 112.5 MG; MOXIDECTIN 5.6 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37540 | 2026-05-15 | Supplement to a New Drug Submission (SNDS) | Additional indication |
| 36058 | 2025-09-26 | New Drug Submission (NDS) | |
Request a quote for BRAVECTO QUANTUM
How to read a Canadian DIN record